3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
4
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Fibromatosis, Gingival, 2
2
Uterine Neoplasms
1
Urinary Bladder Neoplasms
1
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Lung Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Gallbladder Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Bile Duct Neoplasms
1
Adenocarcinoma
1
Interventions
Oxaliplatin
26
Gemcitabine
22
Fluorouracil
17
Capecitabine
16
Leucovorin
15
pembrolizumab
14
Docetaxel
14
Cisplatin
13
Bevacizumab
12
Radiotherapy
8
Paclitaxel
8
Irinotecan
8
Trastuzumab
7
Pemetrexed
6
Carboplatin
6
130-nm albumin-bound paclitaxel
6
durvalumab
5
cemiplimab
5
Erlotinib Hydrochloride
5
Sunitinib
4
Ramucirumab
4
Metformin
4
Gefitinib
4
trastuzumab deruxtecan
3
tislelizumab
3
cabozantinib
3
atezolizumab
3
Taxes
3
Sorafenib
3
Panitumumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Adenocarcinoma
×
seribantumab
×
Clear all
NCT02387216
2021-10-12
SHERLOC
Elevation Oncology
Phase 2
Terminated
153 enrolled
19 charts